Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 9/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511222 | 1.00 | PKM (0.39) | PKMGAAKDM4EFFAR2RIPK1 | |
| SCHEMBL4521465 | 0.80 | FFAR2 (0.38) | FFAR2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4521461 | 0.80 | FFAR2 (0.38) | FFAR2RIPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4520149 | 0.79 | RIPK1 (0.45) | PKMKDM4ERIPK1PDE5AALDH1A1 | |
| SCHEMBL4520150 | 0.79 | RIPK1 (0.45) | PKMKDM4ERIPK1PDE5AALDH1A1 | |
| SCHEMBL4097126 | 0.74 | FFAR2 (0.43) | FFAR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL4514593 | 0.72 | KDM4E (0.42) | GAAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL4509143 | 0.72 | FFAR2 (0.34) | PKMFFAR2RIPK1 | |
| SCHEMBL4509140 | 0.72 | FFAR2 (0.34) | PKMFFAR2RIPK1 | |
| SCHEMBL4509815 | 0.72 | FFAR2 (0.34) | PKMFFAR2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | PKM 3737/4885GAA 1381/4885KDM4E 3761/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | PKM 3737/4885GAA 1381/4885KDM4E 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.